Integrating AI and RNA biomarkers in cancer: advances in diagnostics and targeted therapies

将人工智能和RNA生物标志物整合到癌症治疗中:诊断和靶向治疗的进展

阅读:1

Abstract

Early detection and personalized treatment strategies are essential for enhancing patient outcomes, as cancer continues to be a significant cause of mortality on a global basis. In clinical practice, the identification and validation of reliable biomarkers for cancer diagnosis, prognosis, and therapeutic monitoring continue to present significant challenges. The present study explores the current state and applications of artificial intelligence-driven approaches in the identification and usage of RNA biomarkers for cancer diagnostics and therapeutics. In various aspects of cancer management, we explore the integration of machine learning and deep learning algorithms with a variety of RNA biomarker classes, such as circRNAs, miRNAs, and lncRNAs. Improved detection, subtype categorization, prognosis prediction, and treatment response monitoring are all possible due to AI-powered approaches that can efficiently analyse complex RNA expression patterns, discover novel biomarkers, and explain their functions in cancer biology. There are still many obstacles to overcome in the biomarker development, validation, and clinical application processes, despite the fact that RNA biomarkers hold great potential to transform cancer treatment by improving early detection and individualized therapy methods. Integrating AI with RNA biomarker research is a crucial strategy with enormous promise for precision oncology and better patient care all the way through the cancer spectrum, from risk prediction to recurrence management.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。